{"id":562187,"date":"2026-08-13T14:00:00","date_gmt":"2026-08-13T12:00:00","guid":{"rendered":"https:\/\/medizinonline.com\/treat-to-target-consensus-recommendations-for-gc-tapering-and-the-use-of-dmards\/"},"modified":"2026-08-17T18:01:13","modified_gmt":"2026-08-17T16:01:13","slug":"treat-to-target-consensus-recommendations-for-gc-tapering-and-the-use-of-dmards","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/en\/treat-to-target-consensus-recommendations-for-gc-tapering-and-the-use-of-dmards\/","title":{"rendered":"Treat-to-Target \u2013 Consensus Recommendations for GC Tapering and the Use of DMARDs"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>In addition to the EULAR <em>(European Alliance of Associations for Rheumatology)<\/em>\/ACR <em>(American College of Rheumatology) classification criteria<\/em>, there are other validated tools that facilitate the early detection of SLE, such as SLERPI <em>(SLE Risk Probability Index).<\/em> A key focus of treatment is achieving remission or low disease activity to minimize long-term organ damage. For patients who show an inadequate response to hydroxychloroquine and glucocorticoids, early use of classic immunosuppressants (csDMARDs) or immunomodulatory biologics (bDMARDs), as this strategy yields the best long-term outcomes.  <\/strong><\/p>\n\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/en\/my-account\/packages\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/en\/log-in\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fen%2Ftreat-to-target-consensus-recommendations-for-gc-tapering-and-the-use-of-dmards%2F\">Log in here<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>In addition to the EULAR (European Alliance of Associations for Rheumatology)\/ACR (American College of Rheumatology) classification criteria, there are other validated tools that facilitate the early detection of SLE, such&#8230;&hellip;... <\/p>\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/en\/my-account\/packages\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/en\/log-in\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fen%2Ftreat-to-target-consensus-recommendations-for-gc-tapering-and-the-use-of-dmards%2F\">Log in here<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":562190,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Systemic Lupus (SLE): What Does the Diagnosis and Treatment Toolbox Have to Offer?  ","footnotes":"","_members_access_role":[],"_members_access_error":""},"category":[11548,11513,11297,11413,11480,11503],"tags":[51020,98558,12391,99031,99028,98556,45567,19157,99027,99039,21434,21242,26578,14118,99038,99035,99033,99037,54367,62603],"powerkit_post_featured":[],"class_list":["post-562187","post","type-post","status-publish","format-standard","has-post-thumbnail","category-rx-en","category-congress-reports","category-general-internal-medicine","category-nephrology","category-rheumatology","category-studies","tag-acr-en","tag-bdmards","tag-biologics-en","tag-classification-criteria","tag-consensus-recommendations-2","tag-csdmards","tag-dmards-en","tag-eular-en","tag-gc-tapering","tag-glucocorticoids-2","tag-hydroxychloroquine","tag-immunosuppressants","tag-remission-en","tag-sle-en","tag-sle-disease-activity-index","tag-sle-risk-probability-index","tag-sledai","tag-slerpi","tag-systemic-lupus","tag-treat-to-target-en","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-09-05 19:07:53","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":562193,"slug":"treat-to-target-recommandations-consensuelles-concernant-la-reduction-progressive-de-la-corticotherapie-et-lutilisation-des-dmard","post_title":"\u00ab Treat-to-target \u00bb \u2013 Recommandations consensuelles concernant la r\u00e9duction progressive de la corticoth\u00e9rapie et l'utilisation des DMARD","href":"https:\/\/medizinonline.com\/fr\/treat-to-target-recommandations-consensuelles-concernant-la-reduction-progressive-de-la-corticotherapie-et-lutilisation-des-dmard\/"},"it_IT":{"locale":"it_IT","id":562201,"slug":"treat-to-target-raccomandazioni-di-consenso-sulla-riduzione-graduale-della-gc-e-sulluso-dei-dmard","post_title":"Treat-to-target \u2013 Raccomandazioni di consenso sulla riduzione graduale della GC e sull\u2019uso dei DMARD","href":"https:\/\/medizinonline.com\/it\/treat-to-target-raccomandazioni-di-consenso-sulla-riduzione-graduale-della-gc-e-sulluso-dei-dmard\/"},"pt_PT":{"locale":"pt_PT","id":562211,"slug":"treat-to-target-recomendacoes-consensuais-para-a-reducao-gradual-da-gc-e-a-utilizacao-de-dmards","post_title":"Treat-to-target \u2013 Recomenda\u00e7\u00f5es consensuais para a redu\u00e7\u00e3o gradual da GC e a utiliza\u00e7\u00e3o de DMARDs","href":"https:\/\/medizinonline.com\/pt-pt\/treat-to-target-recomendacoes-consensuais-para-a-reducao-gradual-da-gc-e-a-utilizacao-de-dmards\/"},"es_ES":{"locale":"es_ES","id":562223,"slug":"tratamiento-orientado-a-objetivos-recomendaciones-consensuadas-sobre-la-reduccion-gradual-de-la-corticosteroides-y-el-uso-de-farmacos-antirreumaticos-modificadores-de-la-enfermedad-fame","post_title":"Tratamiento orientado a objetivos: recomendaciones consensuadas sobre la reducci\u00f3n gradual de la corticosteroides y el uso de f\u00e1rmacos antirreum\u00e1ticos modificadores de la enfermedad (FAME)","href":"https:\/\/medizinonline.com\/es\/tratamiento-orientado-a-objetivos-recomendaciones-consensuadas-sobre-la-reduccion-gradual-de-la-corticosteroides-y-el-uso-de-farmacos-antirreumaticos-modificadores-de-la-enfermedad-fame\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/562187","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/comments?post=562187"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/562187\/revisions"}],"predecessor-version":[{"id":562192,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/562187\/revisions\/562192"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media\/562190"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media?parent=562187"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/category?post=562187"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/tags?post=562187"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/powerkit_post_featured?post=562187"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}